H.R. 1352, Increasing Access to Biosimilars Act of 2023
As ordered reported by the House Committee on Energy and Commerce on December 6, 2023
By Fiscal Year, Millions of Dollars
2024
2024-2029
2024-2034
Direct Spending (Outlays)
0
233
227
Revenues
0
0
0
Increase or Decrease (-) in the Deficit
0
233
227
Spending Subject to Appropriation (Outlays)
0
0
not estimated
Increases net direct spending in any of the four consecutive 10-year periods beginning in 2035?
No
Statutory pay-as-you-go procedures apply?
Yes
Mandate Effects
Increases on-budget deficits in any of the four consecutive 10-year periods beginning in 2035?
No
Contains intergovernmental mandate?
No
Contains private-sector mandate?
No
The bill would
Direct the Department of Health and Human Services to implement a demonstration project that would increase Medicare payment rates for biosimilar products covered under Medicare Part B
Estimated budgetary effects would mainly stem from
Increasing Medicare payment rates for biosimilars
Preventing increases in cost sharing for beneficiaries
Areas of significant uncertainty include
Predicting payment rates under the demonstration
Identifying which biosimilars would be used in the demonstration
Projecting effects on biosimilar use and prices after the demonstration
